1. Thymidine kinase in malignant melanoma.
- Author
-
Borovanský J, Stríbrná J, Elleder M, and Netíková I
- Subjects
- Animals, Cell Division, Cyclophosphamide therapeutic use, Cytosol enzymology, Female, Isoenzymes analysis, Liver enzymology, Melanoma, Experimental drug therapy, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Mice, Inbred DBA, Neoplasm Transplantation, Proliferating Cell Nuclear Antigen analysis, Specific Pathogen-Free Organisms, Biomarkers, Tumor analysis, Melanoma, Experimental enzymology, Neoplasm Proteins analysis, Thymidine Kinase analysis
- Abstract
Thymidine kinase (EC 2.7.1.21) is an enzyme supporting DNA synthesis under conditions of increased cell proliferation. Although it has proved to be a useful marker for various malignant diseases, it has not been tested in malignant melanoma. Thymidine kinase activity was measured by means of a radioenzymic assay in two classical animal models of melanoma disease--B16 and Cloudman S91 melanoma-bearing mice. Tumour cell proliferation was assessed histochemically by measuring the expression of proliferating cell nuclear antigen (PCNA). Tumour cytosolic specific thymidine kinase activity was found to be higher in less pigmented Cloudman S91 melanoma than in differentiated, ie pigmented B16 melanoma, relative to the proliferative activity of the two tumours. Serum thymidine kinase levels were increased in melanoma-bearing animals of both types compared with healthy mice; this also reflected the efficacy of the therapy: cyclophosphamide-treated B16 melanoma-bearing mice in which the tumour development was slowed down had significantly lower serum enzyme levels in comparison with the non-treated group and the same levels compared with control, healthy mice. Our results suggest that serum thymidine kinase levels might be used as a marker to follow the effect of melanoma therapy.
- Published
- 1994